Edition:
India

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

61.47USD
22 Jun 2018
Change (% chg)

$0.29 (+0.47%)
Prev Close
$61.18
Open
$61.24
Day's High
$61.91
Day's Low
$61.22
Volume
6,365,112
Avg. Vol
3,524,397
52-wk High
$66.41
52-wk Low
$52.83

Select another date:

Thu, Jun 21 2018

Photo

Novo's pioneering diabetes pill beats Victoza, Januvia in tests

COPENHAGEN Novo Nordisk's experimental diabetes pill, which it hopes will transform the diabetes market, has proved superior to both Merck & Co's Januvia and its own best-selling injectable treatment Victoza in tests.

Merck's Keytruda shows promise in treating advanced melanoma

Merck & Co Inc said on Monday long-term data from its cancer immunotherapy Keytruda showed promise in treating advanced melanoma patients, a day after announcing positive lung cancer data from the same treatment. | Video

Merck's Keytruda shows promise in treating advanced melanoma

June 4 Merck & Co Inc said on Monday long-term data from its cancer immunotherapy Keytruda showed promise in treating advanced melanoma patients, a day after announcing positive lung cancer data from the same treatment.

UPDATE 1-Merck's Keytruda extends lung cancer survival in 2 trials

CHICAGO, June 3 Merck & Co's immunotherapy Keytruda improved survival as a stand-alone treatment for newly-diagnosed lung cancer patients and with chemotherapy for hard-to-treat squamous cell lung cancer, new data released on Sunday showed, further cementing the company's lead in the most lucrative oncology market.

EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

REFILE-EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH, June 1 The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH, June 1 The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

Roche, chasing Merck, notches another lung cancer win

ZURICH Roche's bid to keep Merck's cancer blockbuster Keytruda within striking distance got a lift on Tuesday when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients' survival.

Roche, chasing Merck, notches another lung cancer win

ZURICH Roche's bid to keep Merck's cancer blockbuster Keytruda within striking distance got a lift on Tuesday when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients' survival.

UPDATE 1-Roche, chasing Merck, notches another lung cancer win

* Detailed trial results due later this year (Adds comment from Roche, details, analyst comments)

Select another date: